Which statement about Rasagiline is true?

Which statement about Rasagiline is true?

• A. It is a direct-acting dopamine receptor agonist
• B. It is an MAOI
• C. It is a catecholamine blocker
• D. It is a dopamine precursor

Answer: (B)

Rasagiline increases dopaminergic activity by blocking the enzyme monoamine oxidase B in the brain, reducing dopamine breakdown and raising its availability. This makes Rasagiline an MAOI, specifically an MAO-B inhibitor, used in Parkinson’s disease as initial therapy or as an add-on to levodopa to improve motor symptoms. It isn’t a direct-acting dopamine receptor agonist (that would stimulate receptors directly), nor a dopamine precursor (like levodopa), nor a catecholamine blocker.

Rasagiline increases dopaminergic activity by blocking the enzyme monoamine oxidase B in the brain, reducing dopamine breakdown and raising its availability. This makes Rasagiline an MAOI, specifically an MAO-B inhibitor, used in Parkinson’s disease as initial therapy or as an add-on to levodopa to improve motor symptoms. It isn’t a direct-acting dopamine receptor agonist (that would stimulate receptors directly), nor a dopamine precursor (like levodopa), nor a catecholamine blocker.